GSK

GSK beats Q2 earnings and revenue estimates, reaffirms 2026 guidance and unveils a new cost-saving plan.

GSK plc (GSK) Q2 2026 Earnings Call Transcript

GSK NYSE: GSK reported second-quarter sales growth of 5% at constant exchange rates to more than £8.4 billion, supported by Specialty Medicines and Vaccines, while outlining a new cost-savings and investment program intended to accelerate its late-stage pipeline and support growth beyond 2031.

GSK delivered healthy Q2 and H1 2026 results, with the highlight being core turnover and EPS growth at the upper end of the guidance ranges. However, it's hard to make a Buy case for it anymore as stock metrics like the forward P/E and dividend yield don't offer adequate support. While the company has maintained its long-term sales target, even that isn't encouraging enough from the stock price perspective as only limited price returns are foreseen.

GSK PLC (LSE:GSK, NYSE:GSK) shares jumped to a three-month high after the drugmaker beat second-quarter expectations across its main measures and accelerated investment in its pipeline. Revenue rose 5% to £8.41 billion, ahead of the £8.25 billion City consensus.

GSK (GSK) came out with quarterly earnings of $1.36 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.23 per share a year ago.

The U.K. drugmaker is targeting annual savings of $2.52 billion by 2029, as Chief Executive Luke Miels outlined his roadmap to hit the company's 2031 sales target.

British drugmaker GSK said on Tuesday that it will invest £400 million ($531.12 million) over 3 years ​in the country, including a new R&D ‌center in Cambridge as part of its plans to develop medicines faster under new CEO Luke Miels.

GSK on ​Tuesday said ‌partner Hansoh Pharmaceutical's ​experimental ​drug Ris-Rez met ⁠its main ​goal ​of keeping an aggressive bone ​cancer ​from worsening in ‌a ⁠late-stage trial, just weeks ​after ​it ⁠succeeded in ​another ​advanced ⁠study.

The FTSE 100 Index was little changed this week as investors assessed the escalating UK-Iran crisis, the ongoing US earnings season, and a series of key UK economic releases. Market participants digested the latest jobs, inflation, and retail sales data for July, all of which could influence the Bank of England's next policy decision.